A New Hope for Platinum-Resistant Ovarian Cancer: Raludotatug Deruxtecan Earns FDA Breakthrough Therapy Designation
Ovarian cancer remains one of the most challenging malignancies in gynecologic oncology. For patients whose disease becomes platinum-resistant—meaning that standard […]








